KLC2 and chronic myelogenous leukemia, BCR-ABL1 positive: To elucidate the role of KLC2 MT on CML resistance to TKI, we examined a panel of cell proliferation signaling protein levels in KLC2-WT/R312W/L523I–transduced K562 and KU812 cells with and without imatinib and dasatinib treatments.